3rd PAT and Real Time Quality Summit Philadelphia Airport Marriott, Philadelphia

With drug developers and manufacturers facing closer scrutiny on product quality than ever before, it’s time to make the most of evolving process analytical technology (PAT) to design robust and cost-effective control strategies to understand more about your biopharmaceutical products.

Recent blockbusters like GLP-1 peptides have sparked unprecedented investment into advanced manufacturing strategies, such as Novo Nordisk’s recent $11B acquisition to expand manufacturing capacity. The maturity of PAT tools and the development of sophisticated software and chemometrics now provide the perfect opportunity to revolutionize traditional quality and analytical approaches, achieving the digital manufacturing maturity necessary for the future.